Connect Biopharma Holdings Ltd (CNTB)
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory diseases in the United States. Its lead candidate is rademikibart, formerly known as CBP-201, an antibody designed to target interleukin-4 receptor alpha. The program is currently in Phase 3 studies for conditions including atopic dermatitis and asthma. Founded in 2012, the company is headquartered in San Diego, California. Connect Biopharma Holdings Ltd’s common stock is listed on NASDAQ under the ticker CNTB.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CNTB
|
$1.38
|
13.8% Upside
|
Fair
|
$6.50
|
435.0% Upside
|
Bargain
|
Weak
|
0.0%
|
November 18, 2026
|
3.1x
|
28.1x
|
76.514 M
|
52.236 M
|
0.7%
|
33.5%
|
-15.8
|
87.9%
|
